Get all your news in one place.
100’s of premium titles.
One app.
Start reading
Benzinga
Benzinga
Business
Lisa Levin

Why Snap Shares Are Trading Sharply Lower; Here Are 25 Stocks Moving Premarket

Gainers

  • Statera Biopharma, Inc. (NASDAQ:STAB) rose 40.9% to $0.2160 in pre-market trading. Statera Biopharma recently signed a binding Memorandum of Understanding with Holobeam Technologies Inc.
  • Energy Focus, Inc (NASDAQ:EFOI) shares rose 31.6% to $0.5312 in pre-market trading. Energy Focus, last month, named Lesley Matt as CEO.
  • FedNat Holding Company (NASDAQ:FNHC) rose 18.1% to $0.66 in pre-market trading after dipping over 8% on Thursday.
  • Veris Residential, Inc. (NYSE:VRE) shares rose 18% to $14.65 in pre-market trading. Kushner Cos. offered to acquire Veris Residential for $16 per share, the Wall Street Journal reported.
  • American Rebel Holdings, Inc. (NASDAQ:AREB) rose 16.6% to $0.3389 in pre-market trading. American Rebel shares gained around 5% on Thursday after the company announced it sees $5 million in pro forma Q3 gross revenue.
  • Calliditas Therapeutics AB (NASDAQ:CALT) rose 13.3% to $13.04 in pre-market trading after dipping 15% on Thursday.
  • FaZe Holdings Inc. (NASDAQ:FAZE) shares rose 10.9% to $4.36 in pre-market trading after declining around 9% on Thursday.
  • MEI Pharma, Inc. (NASDAQ:MEIP) rose 9.7% to $0.3583 in pre-market trading. MEI Pharma, last month, posted a FY22 loss of $0.50 per share.
  • Weber Inc. (NYSE:WEBR) rose 7.9% to $5.60 in pre-market trading.
  • Dave Inc. (NASDAQ:DAVE) shares rose 7.7% to $0.35 in pre-market trading. Dave, last month, named Chien-Liang Chou as its New Chief Technology Officer.
  • Senti Biosciences, Inc. (NASDAQ:SNTI) rose 7.3% to $2.64 in pre-market trading after dipping over 10% on Thursday.


Don’t forget to check out our premarket coverage here .


Losers

  • Immunic, Inc. (NASDAQ:IMUX) shares fell 68.8% to $2.87 in pre-market trading after the company reported pre-planned Phase 1b interim analysis of IMU-935 in Psoriasis patients confounded by high placebo rate.
  • Snap Inc. (NYSE:SNAP) shares fell 27.2% to $7.86 in pre-market trading after the company reported its slowest sales growth since going public. Snap announced a $500-million buyback Thursday along with its financial results. The company said due to the “operating environment” it will not provide guidance on revenue or adjusted EBITDA for the fourth quarter.
  • Sientra, Inc. (NASDAQ:SIEN) fell 16.6% to $0.3280 in pre-market trading. Sientra recently announced a proposed public offering.
  • SVB Financial Group (NASDAQ:SIVB) fell 16.5% to $252.63 in pre-market trading after reporting Q3 earnings.
  • SenesTech, Inc. (NASDAQ:SNES) shares fell 14.3% to $0.24 in pre-market trading after declining around 18% on Thursday.
  • Tenet Healthcare Corporation (NYSE:THC) fell 14.1% to $46.68 in pre-market trading after the company issued weak forecast for the year.
  • Kala Pharmaceuticals, Inc. (NASDAQ:KALA) fell 13% to $8.70 in pre-market trading. Kala Pharmaceuticals announced a 1-for-50 reverse stock split.
  • Robert Half International Inc. (NYSE:RHI) shares fell 10.3% to $71.59 in pre-market trading after reporting downbeat Q3 earnings.
  • Invivyd, Inc. (NASDAQ:IVVD) fell 10.1% to $3.30 in pre-market trading after gaining over 12% on Thursday.
  • Zovio Inc (NASDAQ:ZVO) fell 10% to $0.1756 in pre-market trading after declining 7% on Thursday.
  • Green Giant Inc. (NASDAQ:GGE) shares fell 9.9% to $1.83 in pre-market trading.
  • Twitter, Inc. (NYSE:TWTR) shares fell 8.2% to $48.13 in pre-market trading. The U.S. is reportedly discussing the possibility of subjecting Elon Musk’s companies to national security reviews. Musk has also been locked in a battle over buying Twitter. The U.S. government is reportedly unhappy with the billionaire mobilizing financing from foreign high-net-worth individuals to consummate the deal.
  • Pinterest, Inc. (NYSE:PINS) fell 7.4% to $21.28 in pre-market trading in sympathy with Snap, which gave an uncertain fourth-quarter outlook.
  • The Trade Desk, Inc. (NASDAQ:TTD) fell 6.5% to $52.80 in pre-market trading. Morgan Stanley recently initiated coverage on the stock with an Equal-Weight rating and $60 price target.
Sign up to read this article
Read news from 100’s of titles, curated specifically for you.
Already a member? Sign in here
Related Stories
Top stories on inkl right now
One subscription that gives you access to news from hundreds of sites
Already a member? Sign in here
Our Picks
Fourteen days free
Download the app
One app. One membership.
100+ trusted global sources.